A Phase II Trial of the Pan-Her Inhibitor Poziotinib, in Patients With HER2-positive Metastatic Breast Cancer Who Had Received at Least Two Prior HER2-directed Regimens: Results of the NOV120101-203 Trial

International Journal of Cancer - United States
doi 10.1002/ijc.31651
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

A Phase I/Ii Study of Poziotinib Combined With Paclitaxel and Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2019English

The HER2 Phenotype of Circulating Tumor Cells in HER2-positive Early Breast Cancer: A Translational Research Project of a Prospective Randomized Phase III Trial

PLoS ONE
Multidisciplinary
2017English

Validation of the AJCC Prognostic Stage for HER2-positive Breast Cancer in the ShortHER Trial

BMC Medicine
Medicine
2019English

Loss of HER2 Positivity After Anti-Her2 Chemotherapy in HER2-positive Gastric Cancer Patients: Results of the GASTric Cancer HER2 Reassessment Study 3 (GASTHER3)

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2018English

Serum HER2 Levels Determined by Two Methods in Patients With Metastatic Breast Cancer

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2011English

A Phase II Trial of Erlotinib in Combination With Bevacizumab in Patients With Metastatic Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2008English

Therapy Landscape in Patients With Metastatic HER2-Positive Breast Cancer: Data From the PRAEGNANT Real-World Breast Cancer Registry

Cancers
Cancer ResearchOncology
2018English

Efficacy and Safety of CT-P6 Versus Reference Trastuzumab in HER2-positive Early Breast Cancer: Updated Results of a Randomised Phase 3 Trial

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy